Overview
Health science solutions provider's Q4 revenue grew 6% yr/yr to $772 mln
Adjusted EPS for Q4 rose to $1.70 from $1.42 yr/yr
Company initiates full year 2026 guidance, forecasting revenue of $2.96-$2.99 bln
Outlook
Revvity forecasts 2026 revenue between $2.96 bln and $2.99 bln
Company expects 2026 organic revenue growth of 2-3%
Revvity projects 2026 adjusted EPS of $5.35-$5.45
Result Drivers
DIAGNOSTICS GROWTH - Diagnostics segment revenue increased 10%, with 7% organic growth, aiding overall revenue growth
LIFE SCIENCES PERFORMANCE - Life Sciences segment showed 2% revenue growth, but organic revenue was flat
PORTFOLIO TRANSFORMATION - CEO cited portfolio transformation as positioning the company to capitalize on market conditions
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 EPS | $0.87 | ||
Q4 Adjusted EPS continuing operations | $1.70 |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 9 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Revvity Inc is $115.00, about 5.7% above its January 30 closing price of $108.80
The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 18 three months ago
Press Release: ID:nBwkQl67a
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)